Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Marin

Showing results (11-20 of 179) with videos related to

Pageof 18
Sort By:
The New England Journal of Medicine|May 7, 2020
CAR-Transduced Natural Killer Cells. ReplyKatayoun Rezvani, Elizabeth J Shpall, David Marin
Current Opinion in Hematology|January 22, 2013
The next questions in chronic myeloid leukaemia and their answersDavid Marin, Antonia Rotolo, Dragana Milojkovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2011
European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmationDavid Marin, Amr R Ibrahim, John M Goldman
Leukemia Research|November 25, 2010
Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribedLina Eliasson, Sarah Clifford, Nick Barber, et al.
Journal of Insect Physiology|May 17, 2005
Cyclic AMP affects the haemocyte responses of larval Galleria mellonella to selected antigensDavid Marin, Gary B Dunphy, Craig A Mandato
Seminars in Hematology|June 5, 2003
Clinical decisions for chronic myeloid leukemia in the imatinib eraJohn M Goldman, David Marin, Eduardo Olavarria, et al.
Blood|September 25, 2003
Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional dosesDavid Marin, John M Goldman, Eduardo Olavarria, et al.
Lancet (London, England)|April 15, 2004
Interactive web-based guidelines for chronic myeloid leukaemiaDavid Marin, Amin Rahemtulla, Eduardo Olavarria, et al.
Lancet (London, England)|July 18, 2003
Imatinib or transplant for chronic myeloid leukaemia?John Goldman, Jane Apperley, Edward Kanfer, et al.
Haematologica|April 26, 2012
Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapyPratap Neelakantan, David Marin, Mike Laffan, et al.
Pageof 18

Showing results (11-20 of 179) with videos related to

Sort By:
Pageof 18
The New England Journal of Medicine|May 7, 2020
CAR-Transduced Natural Killer Cells. ReplyKatayoun Rezvani, Elizabeth J Shpall, David Marin
Current Opinion in Hematology|January 22, 2013
The next questions in chronic myeloid leukaemia and their answersDavid Marin, Antonia Rotolo, Dragana Milojkovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2011
European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmationDavid Marin, Amr R Ibrahim, John M Goldman
Leukemia Research|November 25, 2010
Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribedLina Eliasson, Sarah Clifford, Nick Barber, et al.
Journal of Insect Physiology|May 17, 2005
Cyclic AMP affects the haemocyte responses of larval Galleria mellonella to selected antigensDavid Marin, Gary B Dunphy, Craig A Mandato
Seminars in Hematology|June 5, 2003
Clinical decisions for chronic myeloid leukemia in the imatinib eraJohn M Goldman, David Marin, Eduardo Olavarria, et al.
Blood|September 25, 2003
Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional dosesDavid Marin, John M Goldman, Eduardo Olavarria, et al.
Lancet (London, England)|April 15, 2004
Interactive web-based guidelines for chronic myeloid leukaemiaDavid Marin, Amin Rahemtulla, Eduardo Olavarria, et al.
Lancet (London, England)|July 18, 2003
Imatinib or transplant for chronic myeloid leukaemia?John Goldman, Jane Apperley, Edward Kanfer, et al.
Haematologica|April 26, 2012
Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapyPratap Neelakantan, David Marin, Mike Laffan, et al.
Pageof 18